Clinical Research Trials Archive – Closed Trials

This is our archive of closed clinical trials, which means that they are no longer accepting new participants or have been concluded. Once a research facility has chosen to close the study, it is sorted into the GPS archive by indication. If you are interested in enrolling in a clinical trial, then please browse our list of active clinical studies.

Zip code

Condition


Search Radius:25 Miles
  • 5
  • 10
  • 15
  • 20
  • 25
  • 30
  • 40
  • 50
  • 100
  • 500
  • All

We've found
161,353
archived clinical trials in
Cancer

A Study of Regorafenib in Advanced Pancreatic Cancer Patients
A Pilot Study Testing Single-Agent Regorafenib in Advanced Previously-Treated Adenocarcinoma of the Pancreas
Status: Enrolling
Updated:  3/19/2018
Levine Cancer Institute - Cleveland
mi
from
Shelby, NC
A Study of Regorafenib in Advanced Pancreatic Cancer Patients
A Pilot Study Testing Single-Agent Regorafenib in Advanced Previously-Treated Adenocarcinoma of the Pancreas
Status: Enrolling
Updated: 3/19/2018
Levine Cancer Institute - Cleveland
mi
from
Shelby, NC
Click here to add this to my saved trials
A Study of Regorafenib in Advanced Pancreatic Cancer Patients
A Pilot Study Testing Single-Agent Regorafenib in Advanced Previously-Treated Adenocarcinoma of the Pancreas
Status: Enrolling
Updated:  3/19/2018
Low Country Hematology Oncology
mi
from
Charleston, SC
A Study of Regorafenib in Advanced Pancreatic Cancer Patients
A Pilot Study Testing Single-Agent Regorafenib in Advanced Previously-Treated Adenocarcinoma of the Pancreas
Status: Enrolling
Updated: 3/19/2018
Low Country Hematology Oncology
mi
from
Charleston, SC
Click here to add this to my saved trials
Dignity Therapy/Life Plan in Patients With Pancreatic or Advanced Lung Cancer
Phase I/IIA: Dignity Therapy/Life Plan in Patients With Pancreatic or Advanced Lung Cancer
Status: Enrolling
Updated:  3/19/2018
The Mayo Clinic
mi
from
Rochester, MN
Dignity Therapy/Life Plan in Patients With Pancreatic or Advanced Lung Cancer
Phase I/IIA: Dignity Therapy/Life Plan in Patients With Pancreatic or Advanced Lung Cancer
Status: Enrolling
Updated: 3/19/2018
The Mayo Clinic
mi
from
Rochester, MN
Click here to add this to my saved trials
Integrated Versus Standard Palliative Care in Patients With Advanced Non-small Cell Lung Cancer (NSCLC)
A Randomized, Controlled Trial of Integrated vs. Standard Palliative Care in Patients With Advanced NSCLC
Status: Enrolling
Updated:  3/19/2018
Massachusetts General Hospital
mi
from
Boston, MA
Integrated Versus Standard Palliative Care in Patients With Advanced Non-small Cell Lung Cancer (NSCLC)
A Randomized, Controlled Trial of Integrated vs. Standard Palliative Care in Patients With Advanced NSCLC
Status: Enrolling
Updated: 3/19/2018
Massachusetts General Hospital
mi
from
Boston, MA
Click here to add this to my saved trials
Dasatinib in Treating Patients With Advanced Liver Cancer That Cannot Be Removed by Surgery
A Phase II Trial of Dasatinib (BMS-354825) in Advanced Hepatocellular Carcinoma
Status: Enrolling
Updated:  3/20/2018
University of Southern California - Norris
mi
from
Los Angeles, CA
Dasatinib in Treating Patients With Advanced Liver Cancer That Cannot Be Removed by Surgery
A Phase II Trial of Dasatinib (BMS-354825) in Advanced Hepatocellular Carcinoma
Status: Enrolling
Updated: 3/20/2018
University of Southern California - Norris
mi
from
Los Angeles, CA
Click here to add this to my saved trials
Evaluation of Robot-Assisted Surgery in Gynecologic Oncology
Prospective Evaluation of Robot-Assisted Surgery in Gynecologic Oncology
Status: Enrolling
Updated:  3/20/2018
MD Anderson Banner Arizona
mi
from
Gilbert, AZ
Evaluation of Robot-Assisted Surgery in Gynecologic Oncology
Prospective Evaluation of Robot-Assisted Surgery in Gynecologic Oncology
Status: Enrolling
Updated: 3/20/2018
MD Anderson Banner Arizona
mi
from
Gilbert, AZ
Click here to add this to my saved trials
Evaluation of Robot-Assisted Surgery in Gynecologic Oncology
Prospective Evaluation of Robot-Assisted Surgery in Gynecologic Oncology
Status: Enrolling
Updated:  3/20/2018
University of Texas M.D. Anderson Cancer Center
mi
from
Houston, TX
Evaluation of Robot-Assisted Surgery in Gynecologic Oncology
Prospective Evaluation of Robot-Assisted Surgery in Gynecologic Oncology
Status: Enrolling
Updated: 3/20/2018
University of Texas M.D. Anderson Cancer Center
mi
from
Houston, TX
Click here to add this to my saved trials
Study of Fractionated Stereotactic Radiosurgery to Treat Large Brain Metastases
A Phase I/II Study of Fractionated Stereotactic Radiosurgery to Treat Large Brain Metastases
Status: Enrolling
Updated:  3/20/2018
Stanford University School of Medicine
mi
from
Stanford, CA
Study of Fractionated Stereotactic Radiosurgery to Treat Large Brain Metastases
A Phase I/II Study of Fractionated Stereotactic Radiosurgery to Treat Large Brain Metastases
Status: Enrolling
Updated: 3/20/2018
Stanford University School of Medicine
mi
from
Stanford, CA
Click here to add this to my saved trials
P1/2 of Temozolomide and Hypofractionated Radiotherapy in Tx of Supratentorial Glioblastoma Multiform
A Phase 1/2 Trial of Temozolomide and Hypofractionated Radiotherapy in Treatment of Supratentorial Glioblastoma Multiforme
Status: Enrolling
Updated:  3/20/2018
Stanford University School of Medicine
mi
from
Stanford, CA
P1/2 of Temozolomide and Hypofractionated Radiotherapy in Tx of Supratentorial Glioblastoma Multiform
A Phase 1/2 Trial of Temozolomide and Hypofractionated Radiotherapy in Treatment of Supratentorial Glioblastoma Multiforme
Status: Enrolling
Updated: 3/20/2018
Stanford University School of Medicine
mi
from
Stanford, CA
Click here to add this to my saved trials
STA-9090 in Previously Treated Patients With Advanced Esophagogastric Cancer
A Phase 2 Clinical Trial of STA-9090 in Previously Treated Patients With Advanced Esophagogastric Cancers
Status: Enrolling
Updated:  3/20/2018
Massachusetts General Hospital
mi
from
Boston, MA
STA-9090 in Previously Treated Patients With Advanced Esophagogastric Cancer
A Phase 2 Clinical Trial of STA-9090 in Previously Treated Patients With Advanced Esophagogastric Cancers
Status: Enrolling
Updated: 3/20/2018
Massachusetts General Hospital
mi
from
Boston, MA
Click here to add this to my saved trials
STA-9090 in Previously Treated Patients With Advanced Esophagogastric Cancer
A Phase 2 Clinical Trial of STA-9090 in Previously Treated Patients With Advanced Esophagogastric Cancers
Status: Enrolling
Updated:  3/20/2018
Dana-Farber Cancer Institute
mi
from
Boston, MA
STA-9090 in Previously Treated Patients With Advanced Esophagogastric Cancer
A Phase 2 Clinical Trial of STA-9090 in Previously Treated Patients With Advanced Esophagogastric Cancers
Status: Enrolling
Updated: 3/20/2018
Dana-Farber Cancer Institute
mi
from
Boston, MA
Click here to add this to my saved trials
STA-9090 in Previously Treated Patients With Advanced Esophagogastric Cancer
A Phase 2 Clinical Trial of STA-9090 in Previously Treated Patients With Advanced Esophagogastric Cancers
Status: Enrolling
Updated:  3/20/2018
Beth Israel Deaconess Medical Center
mi
from
Boston, MA
STA-9090 in Previously Treated Patients With Advanced Esophagogastric Cancer
A Phase 2 Clinical Trial of STA-9090 in Previously Treated Patients With Advanced Esophagogastric Cancers
Status: Enrolling
Updated: 3/20/2018
Beth Israel Deaconess Medical Center
mi
from
Boston, MA
Click here to add this to my saved trials
Ixabepilone in Treating Patients With Recurrent or Persistent Uterine Cancer
A Phase II Evaluation of Ixabepilone (NSC #710428) in the Treatment of Recurrent or Persistent Carcinosarcoma of the Uterus
Status: Enrolling
Updated:  3/20/2018
University of Arkansas for Medical Sciences
mi
from
Little Rock, AR
Ixabepilone in Treating Patients With Recurrent or Persistent Uterine Cancer
A Phase II Evaluation of Ixabepilone (NSC #710428) in the Treatment of Recurrent or Persistent Carcinosarcoma of the Uterus
Status: Enrolling
Updated: 3/20/2018
University of Arkansas for Medical Sciences
mi
from
Little Rock, AR
Click here to add this to my saved trials
Ixabepilone in Treating Patients With Recurrent or Persistent Uterine Cancer
A Phase II Evaluation of Ixabepilone (NSC #710428) in the Treatment of Recurrent or Persistent Carcinosarcoma of the Uterus
Status: Enrolling
Updated:  3/20/2018
John Muir Medical Center - Concord Campus
mi
from
Concord, CA
Ixabepilone in Treating Patients With Recurrent or Persistent Uterine Cancer
A Phase II Evaluation of Ixabepilone (NSC #710428) in the Treatment of Recurrent or Persistent Carcinosarcoma of the Uterus
Status: Enrolling
Updated: 3/20/2018
John Muir Medical Center - Concord Campus
mi
from
Concord, CA
Click here to add this to my saved trials
Ixabepilone in Treating Patients With Recurrent or Persistent Uterine Cancer
A Phase II Evaluation of Ixabepilone (NSC #710428) in the Treatment of Recurrent or Persistent Carcinosarcoma of the Uterus
Status: Enrolling
Updated:  3/20/2018
The Hartford Hospital
mi
from
Hartford, CT
Ixabepilone in Treating Patients With Recurrent or Persistent Uterine Cancer
A Phase II Evaluation of Ixabepilone (NSC #710428) in the Treatment of Recurrent or Persistent Carcinosarcoma of the Uterus
Status: Enrolling
Updated: 3/20/2018
The Hartford Hospital
mi
from
Hartford, CT
Click here to add this to my saved trials
Ixabepilone in Treating Patients With Recurrent or Persistent Uterine Cancer
A Phase II Evaluation of Ixabepilone (NSC #710428) in the Treatment of Recurrent or Persistent Carcinosarcoma of the Uterus
Status: Enrolling
Updated:  3/20/2018
The Hospital of Central Connecticut
mi
from
New Britain, CT
Ixabepilone in Treating Patients With Recurrent or Persistent Uterine Cancer
A Phase II Evaluation of Ixabepilone (NSC #710428) in the Treatment of Recurrent or Persistent Carcinosarcoma of the Uterus
Status: Enrolling
Updated: 3/20/2018
The Hospital of Central Connecticut
mi
from
New Britain, CT
Click here to add this to my saved trials
Ixabepilone in Treating Patients With Recurrent or Persistent Uterine Cancer
A Phase II Evaluation of Ixabepilone (NSC #710428) in the Treatment of Recurrent or Persistent Carcinosarcoma of the Uterus
Status: Enrolling
Updated:  3/20/2018
Rush University Medical Center
mi
from
Chicago, IL
Ixabepilone in Treating Patients With Recurrent or Persistent Uterine Cancer
A Phase II Evaluation of Ixabepilone (NSC #710428) in the Treatment of Recurrent or Persistent Carcinosarcoma of the Uterus
Status: Enrolling
Updated: 3/20/2018
Rush University Medical Center
mi
from
Chicago, IL
Click here to add this to my saved trials
Ixabepilone in Treating Patients With Recurrent or Persistent Uterine Cancer
A Phase II Evaluation of Ixabepilone (NSC #710428) in the Treatment of Recurrent or Persistent Carcinosarcoma of the Uterus
Status: Enrolling
Updated:  3/20/2018
University of Chicago Comprehensive Cancer Center
mi
from
Chicago, IL
Ixabepilone in Treating Patients With Recurrent or Persistent Uterine Cancer
A Phase II Evaluation of Ixabepilone (NSC #710428) in the Treatment of Recurrent or Persistent Carcinosarcoma of the Uterus
Status: Enrolling
Updated: 3/20/2018
University of Chicago Comprehensive Cancer Center
mi
from
Chicago, IL
Click here to add this to my saved trials
Ixabepilone in Treating Patients With Recurrent or Persistent Uterine Cancer
A Phase II Evaluation of Ixabepilone (NSC #710428) in the Treatment of Recurrent or Persistent Carcinosarcoma of the Uterus
Status: Enrolling
Updated:  3/20/2018
Sudarshan K Sharma MD Limted-Gynecologic Oncology
mi
from
Hinsdale, IL
Ixabepilone in Treating Patients With Recurrent or Persistent Uterine Cancer
A Phase II Evaluation of Ixabepilone (NSC #710428) in the Treatment of Recurrent or Persistent Carcinosarcoma of the Uterus
Status: Enrolling
Updated: 3/20/2018
Sudarshan K Sharma MD Limted-Gynecologic Oncology
mi
from
Hinsdale, IL
Click here to add this to my saved trials
Ixabepilone in Treating Patients With Recurrent or Persistent Uterine Cancer
A Phase II Evaluation of Ixabepilone (NSC #710428) in the Treatment of Recurrent or Persistent Carcinosarcoma of the Uterus
Status: Enrolling
Updated:  3/20/2018
Mercy Cancer Center - West Lakes
mi
from
Clive, IA
Ixabepilone in Treating Patients With Recurrent or Persistent Uterine Cancer
A Phase II Evaluation of Ixabepilone (NSC #710428) in the Treatment of Recurrent or Persistent Carcinosarcoma of the Uterus
Status: Enrolling
Updated: 3/20/2018
Mercy Cancer Center - West Lakes
mi
from
Clive, IA
Click here to add this to my saved trials
Ixabepilone in Treating Patients With Recurrent or Persistent Uterine Cancer
A Phase II Evaluation of Ixabepilone (NSC #710428) in the Treatment of Recurrent or Persistent Carcinosarcoma of the Uterus
Status: Enrolling
Updated:  3/20/2018
Iowa Lutheran Hospital
mi
from
Des Moines, IA
Ixabepilone in Treating Patients With Recurrent or Persistent Uterine Cancer
A Phase II Evaluation of Ixabepilone (NSC #710428) in the Treatment of Recurrent or Persistent Carcinosarcoma of the Uterus
Status: Enrolling
Updated: 3/20/2018
Iowa Lutheran Hospital
mi
from
Des Moines, IA
Click here to add this to my saved trials
Ixabepilone in Treating Patients With Recurrent or Persistent Uterine Cancer
A Phase II Evaluation of Ixabepilone (NSC #710428) in the Treatment of Recurrent or Persistent Carcinosarcoma of the Uterus
Status: Enrolling
Updated:  3/20/2018
Iowa Methodist Medical Center
mi
from
Des Moines, IA
Ixabepilone in Treating Patients With Recurrent or Persistent Uterine Cancer
A Phase II Evaluation of Ixabepilone (NSC #710428) in the Treatment of Recurrent or Persistent Carcinosarcoma of the Uterus
Status: Enrolling
Updated: 3/20/2018
Iowa Methodist Medical Center
mi
from
Des Moines, IA
Click here to add this to my saved trials
Ixabepilone in Treating Patients With Recurrent or Persistent Uterine Cancer
A Phase II Evaluation of Ixabepilone (NSC #710428) in the Treatment of Recurrent or Persistent Carcinosarcoma of the Uterus
Status: Enrolling
Updated:  3/20/2018
Mercy Medical Center - Des Moines
mi
from
Des Moines, IA
Ixabepilone in Treating Patients With Recurrent or Persistent Uterine Cancer
A Phase II Evaluation of Ixabepilone (NSC #710428) in the Treatment of Recurrent or Persistent Carcinosarcoma of the Uterus
Status: Enrolling
Updated: 3/20/2018
Mercy Medical Center - Des Moines
mi
from
Des Moines, IA
Click here to add this to my saved trials
Ixabepilone in Treating Patients With Recurrent or Persistent Uterine Cancer
A Phase II Evaluation of Ixabepilone (NSC #710428) in the Treatment of Recurrent or Persistent Carcinosarcoma of the Uterus
Status: Enrolling
Updated:  3/20/2018
Mercy Medical Center-West Lakes
mi
from
West Des Moines, IA
Ixabepilone in Treating Patients With Recurrent or Persistent Uterine Cancer
A Phase II Evaluation of Ixabepilone (NSC #710428) in the Treatment of Recurrent or Persistent Carcinosarcoma of the Uterus
Status: Enrolling
Updated: 3/20/2018
Mercy Medical Center-West Lakes
mi
from
West Des Moines, IA
Click here to add this to my saved trials
Ixabepilone in Treating Patients With Recurrent or Persistent Uterine Cancer
A Phase II Evaluation of Ixabepilone (NSC #710428) in the Treatment of Recurrent or Persistent Carcinosarcoma of the Uterus
Status: Enrolling
Updated:  3/20/2018
Methodist West Hospital
mi
from
West Des Moines, IA
Ixabepilone in Treating Patients With Recurrent or Persistent Uterine Cancer
A Phase II Evaluation of Ixabepilone (NSC #710428) in the Treatment of Recurrent or Persistent Carcinosarcoma of the Uterus
Status: Enrolling
Updated: 3/20/2018
Methodist West Hospital
mi
from
West Des Moines, IA
Click here to add this to my saved trials
Ixabepilone in Treating Patients With Recurrent or Persistent Uterine Cancer
A Phase II Evaluation of Ixabepilone (NSC #710428) in the Treatment of Recurrent or Persistent Carcinosarcoma of the Uterus
Status: Enrolling
Updated:  3/20/2018
Sinai Hospital of Baltimore
mi
from
Baltimore, MD
Ixabepilone in Treating Patients With Recurrent or Persistent Uterine Cancer
A Phase II Evaluation of Ixabepilone (NSC #710428) in the Treatment of Recurrent or Persistent Carcinosarcoma of the Uterus
Status: Enrolling
Updated: 3/20/2018
Sinai Hospital of Baltimore
mi
from
Baltimore, MD
Click here to add this to my saved trials
Ixabepilone in Treating Patients With Recurrent or Persistent Uterine Cancer
A Phase II Evaluation of Ixabepilone (NSC #710428) in the Treatment of Recurrent or Persistent Carcinosarcoma of the Uterus
Status: Enrolling
Updated:  3/20/2018
Saint Joseph Mercy Hospital
mi
from
Ann Arbor, MI
Ixabepilone in Treating Patients With Recurrent or Persistent Uterine Cancer
A Phase II Evaluation of Ixabepilone (NSC #710428) in the Treatment of Recurrent or Persistent Carcinosarcoma of the Uterus
Status: Enrolling
Updated: 3/20/2018
Saint Joseph Mercy Hospital
mi
from
Ann Arbor, MI
Click here to add this to my saved trials
Ixabepilone in Treating Patients With Recurrent or Persistent Uterine Cancer
A Phase II Evaluation of Ixabepilone (NSC #710428) in the Treatment of Recurrent or Persistent Carcinosarcoma of the Uterus
Status: Enrolling
Updated:  3/20/2018
Saint John Hospital and Medical Center
mi
from
Detroit, MI
Ixabepilone in Treating Patients With Recurrent or Persistent Uterine Cancer
A Phase II Evaluation of Ixabepilone (NSC #710428) in the Treatment of Recurrent or Persistent Carcinosarcoma of the Uterus
Status: Enrolling
Updated: 3/20/2018
Saint John Hospital and Medical Center
mi
from
Detroit, MI
Click here to add this to my saved trials
Ixabepilone in Treating Patients With Recurrent or Persistent Uterine Cancer
A Phase II Evaluation of Ixabepilone (NSC #710428) in the Treatment of Recurrent or Persistent Carcinosarcoma of the Uterus
Status: Enrolling
Updated:  3/20/2018
Genesys Regional Medical Center-West Flint Campus
mi
from
Flint, MI
Ixabepilone in Treating Patients With Recurrent or Persistent Uterine Cancer
A Phase II Evaluation of Ixabepilone (NSC #710428) in the Treatment of Recurrent or Persistent Carcinosarcoma of the Uterus
Status: Enrolling
Updated: 3/20/2018
Genesys Regional Medical Center-West Flint Campus
mi
from
Flint, MI
Click here to add this to my saved trials
Ixabepilone in Treating Patients With Recurrent or Persistent Uterine Cancer
A Phase II Evaluation of Ixabepilone (NSC #710428) in the Treatment of Recurrent or Persistent Carcinosarcoma of the Uterus
Status: Enrolling
Updated:  3/20/2018
Genesys Hurley Cancer Institute
mi
from
Flint, MI
Ixabepilone in Treating Patients With Recurrent or Persistent Uterine Cancer
A Phase II Evaluation of Ixabepilone (NSC #710428) in the Treatment of Recurrent or Persistent Carcinosarcoma of the Uterus
Status: Enrolling
Updated: 3/20/2018
Genesys Hurley Cancer Institute
mi
from
Flint, MI
Click here to add this to my saved trials
Ixabepilone in Treating Patients With Recurrent or Persistent Uterine Cancer
A Phase II Evaluation of Ixabepilone (NSC #710428) in the Treatment of Recurrent or Persistent Carcinosarcoma of the Uterus
Status: Enrolling
Updated:  3/20/2018
Hurley Medical Center
mi
from
Flint, MI
Ixabepilone in Treating Patients With Recurrent or Persistent Uterine Cancer
A Phase II Evaluation of Ixabepilone (NSC #710428) in the Treatment of Recurrent or Persistent Carcinosarcoma of the Uterus
Status: Enrolling
Updated: 3/20/2018
Hurley Medical Center
mi
from
Flint, MI
Click here to add this to my saved trials
Ixabepilone in Treating Patients With Recurrent or Persistent Uterine Cancer
A Phase II Evaluation of Ixabepilone (NSC #710428) in the Treatment of Recurrent or Persistent Carcinosarcoma of the Uterus
Status: Enrolling
Updated:  3/20/2018
Genesys Regional Medical Center
mi
from
Grand Blanc, MI
Ixabepilone in Treating Patients With Recurrent or Persistent Uterine Cancer
A Phase II Evaluation of Ixabepilone (NSC #710428) in the Treatment of Recurrent or Persistent Carcinosarcoma of the Uterus
Status: Enrolling
Updated: 3/20/2018
Genesys Regional Medical Center
mi
from
Grand Blanc, MI
Click here to add this to my saved trials
Ixabepilone in Treating Patients With Recurrent or Persistent Uterine Cancer
A Phase II Evaluation of Ixabepilone (NSC #710428) in the Treatment of Recurrent or Persistent Carcinosarcoma of the Uterus
Status: Enrolling
Updated:  3/20/2018
Allegiance Health
mi
from
Jackson, MI
Ixabepilone in Treating Patients With Recurrent or Persistent Uterine Cancer
A Phase II Evaluation of Ixabepilone (NSC #710428) in the Treatment of Recurrent or Persistent Carcinosarcoma of the Uterus
Status: Enrolling
Updated: 3/20/2018
Allegiance Health
mi
from
Jackson, MI
Click here to add this to my saved trials
Ixabepilone in Treating Patients With Recurrent or Persistent Uterine Cancer
A Phase II Evaluation of Ixabepilone (NSC #710428) in the Treatment of Recurrent or Persistent Carcinosarcoma of the Uterus
Status: Enrolling
Updated:  3/20/2018
Bronson Methodist Hospital
mi
from
Kalamazoo, MI
Ixabepilone in Treating Patients With Recurrent or Persistent Uterine Cancer
A Phase II Evaluation of Ixabepilone (NSC #710428) in the Treatment of Recurrent or Persistent Carcinosarcoma of the Uterus
Status: Enrolling
Updated: 3/20/2018
Bronson Methodist Hospital
mi
from
Kalamazoo, MI
Click here to add this to my saved trials
Ixabepilone in Treating Patients With Recurrent or Persistent Uterine Cancer
A Phase II Evaluation of Ixabepilone (NSC #710428) in the Treatment of Recurrent or Persistent Carcinosarcoma of the Uterus
Status: Enrolling
Updated:  3/20/2018
Borgess Medical Center
mi
from
Kalamazoo, MI
Ixabepilone in Treating Patients With Recurrent or Persistent Uterine Cancer
A Phase II Evaluation of Ixabepilone (NSC #710428) in the Treatment of Recurrent or Persistent Carcinosarcoma of the Uterus
Status: Enrolling
Updated: 3/20/2018
Borgess Medical Center
mi
from
Kalamazoo, MI
Click here to add this to my saved trials
Ixabepilone in Treating Patients With Recurrent or Persistent Uterine Cancer
A Phase II Evaluation of Ixabepilone (NSC #710428) in the Treatment of Recurrent or Persistent Carcinosarcoma of the Uterus
Status: Enrolling
Updated:  3/20/2018
West Michigan Cancer Center
mi
from
Kalamazoo, MI
Ixabepilone in Treating Patients With Recurrent or Persistent Uterine Cancer
A Phase II Evaluation of Ixabepilone (NSC #710428) in the Treatment of Recurrent or Persistent Carcinosarcoma of the Uterus
Status: Enrolling
Updated: 3/20/2018
West Michigan Cancer Center
mi
from
Kalamazoo, MI
Click here to add this to my saved trials
Ixabepilone in Treating Patients With Recurrent or Persistent Uterine Cancer
A Phase II Evaluation of Ixabepilone (NSC #710428) in the Treatment of Recurrent or Persistent Carcinosarcoma of the Uterus
Status: Enrolling
Updated:  3/20/2018
Sparrow Hospital
mi
from
Lansing, MI
Ixabepilone in Treating Patients With Recurrent or Persistent Uterine Cancer
A Phase II Evaluation of Ixabepilone (NSC #710428) in the Treatment of Recurrent or Persistent Carcinosarcoma of the Uterus
Status: Enrolling
Updated: 3/20/2018
Sparrow Hospital
mi
from
Lansing, MI
Click here to add this to my saved trials
Ixabepilone in Treating Patients With Recurrent or Persistent Uterine Cancer
A Phase II Evaluation of Ixabepilone (NSC #710428) in the Treatment of Recurrent or Persistent Carcinosarcoma of the Uterus
Status: Enrolling
Updated:  3/20/2018
Saint Mary's of Michigan
mi
from
Saginaw, MI
Ixabepilone in Treating Patients With Recurrent or Persistent Uterine Cancer
A Phase II Evaluation of Ixabepilone (NSC #710428) in the Treatment of Recurrent or Persistent Carcinosarcoma of the Uterus
Status: Enrolling
Updated: 3/20/2018
Saint Mary's of Michigan
mi
from
Saginaw, MI
Click here to add this to my saved trials
Ixabepilone in Treating Patients With Recurrent or Persistent Uterine Cancer
A Phase II Evaluation of Ixabepilone (NSC #710428) in the Treatment of Recurrent or Persistent Carcinosarcoma of the Uterus
Status: Enrolling
Updated:  3/20/2018
Saint John Macomb-Oakland Hospital
mi
from
Warren, MI
Ixabepilone in Treating Patients With Recurrent or Persistent Uterine Cancer
A Phase II Evaluation of Ixabepilone (NSC #710428) in the Treatment of Recurrent or Persistent Carcinosarcoma of the Uterus
Status: Enrolling
Updated: 3/20/2018
Saint John Macomb-Oakland Hospital
mi
from
Warren, MI
Click here to add this to my saved trials
Ixabepilone in Treating Patients With Recurrent or Persistent Uterine Cancer
A Phase II Evaluation of Ixabepilone (NSC #710428) in the Treatment of Recurrent or Persistent Carcinosarcoma of the Uterus
Status: Enrolling
Updated:  3/20/2018
University of Mississippi Medical Center
mi
from
Jackson, MS
Ixabepilone in Treating Patients With Recurrent or Persistent Uterine Cancer
A Phase II Evaluation of Ixabepilone (NSC #710428) in the Treatment of Recurrent or Persistent Carcinosarcoma of the Uterus
Status: Enrolling
Updated: 3/20/2018
University of Mississippi Medical Center
mi
from
Jackson, MS
Click here to add this to my saved trials
Ixabepilone in Treating Patients With Recurrent or Persistent Uterine Cancer
A Phase II Evaluation of Ixabepilone (NSC #710428) in the Treatment of Recurrent or Persistent Carcinosarcoma of the Uterus
Status: Enrolling
Updated:  3/20/2018
Washington University School of Medicine
mi
from
Saint Louis, MO
Ixabepilone in Treating Patients With Recurrent or Persistent Uterine Cancer
A Phase II Evaluation of Ixabepilone (NSC #710428) in the Treatment of Recurrent or Persistent Carcinosarcoma of the Uterus
Status: Enrolling
Updated: 3/20/2018
Washington University School of Medicine
mi
from
Saint Louis, MO
Click here to add this to my saved trials
Ixabepilone in Treating Patients With Recurrent or Persistent Uterine Cancer
A Phase II Evaluation of Ixabepilone (NSC #710428) in the Treatment of Recurrent or Persistent Carcinosarcoma of the Uterus
Status: Enrolling
Updated:  3/20/2018
Saint Louis Cancer and Breast Institute-South City
mi
from
Saint Louis, MO
Ixabepilone in Treating Patients With Recurrent or Persistent Uterine Cancer
A Phase II Evaluation of Ixabepilone (NSC #710428) in the Treatment of Recurrent or Persistent Carcinosarcoma of the Uterus
Status: Enrolling
Updated: 3/20/2018
Saint Louis Cancer and Breast Institute-South City
mi
from
Saint Louis, MO
Click here to add this to my saved trials
Ixabepilone in Treating Patients With Recurrent or Persistent Uterine Cancer
A Phase II Evaluation of Ixabepilone (NSC #710428) in the Treatment of Recurrent or Persistent Carcinosarcoma of the Uterus
Status: Enrolling
Updated:  3/20/2018
Mercy Hospital Springfield
mi
from
Springfield, MO
Ixabepilone in Treating Patients With Recurrent or Persistent Uterine Cancer
A Phase II Evaluation of Ixabepilone (NSC #710428) in the Treatment of Recurrent or Persistent Carcinosarcoma of the Uterus
Status: Enrolling
Updated: 3/20/2018
Mercy Hospital Springfield
mi
from
Springfield, MO
Click here to add this to my saved trials
Ixabepilone in Treating Patients With Recurrent or Persistent Uterine Cancer
A Phase II Evaluation of Ixabepilone (NSC #710428) in the Treatment of Recurrent or Persistent Carcinosarcoma of the Uterus
Status: Enrolling
Updated:  3/20/2018
Nebraska Methodist Hospital
mi
from
Omaha, NE
Ixabepilone in Treating Patients With Recurrent or Persistent Uterine Cancer
A Phase II Evaluation of Ixabepilone (NSC #710428) in the Treatment of Recurrent or Persistent Carcinosarcoma of the Uterus
Status: Enrolling
Updated: 3/20/2018
Nebraska Methodist Hospital
mi
from
Omaha, NE
Click here to add this to my saved trials
Ixabepilone in Treating Patients With Recurrent or Persistent Uterine Cancer
A Phase II Evaluation of Ixabepilone (NSC #710428) in the Treatment of Recurrent or Persistent Carcinosarcoma of the Uterus
Status: Enrolling
Updated:  3/20/2018
Women's Cancer Center of Nevada
mi
from
Las Vegas, NV
Ixabepilone in Treating Patients With Recurrent or Persistent Uterine Cancer
A Phase II Evaluation of Ixabepilone (NSC #710428) in the Treatment of Recurrent or Persistent Carcinosarcoma of the Uterus
Status: Enrolling
Updated: 3/20/2018
Women's Cancer Center of Nevada
mi
from
Las Vegas, NV
Click here to add this to my saved trials
Ixabepilone in Treating Patients With Recurrent or Persistent Uterine Cancer
A Phase II Evaluation of Ixabepilone (NSC #710428) in the Treatment of Recurrent or Persistent Carcinosarcoma of the Uterus
Status: Enrolling
Updated:  3/20/2018
State University of New York - Downstate Medical Center
mi
from
Brooklyn, NY
Ixabepilone in Treating Patients With Recurrent or Persistent Uterine Cancer
A Phase II Evaluation of Ixabepilone (NSC #710428) in the Treatment of Recurrent or Persistent Carcinosarcoma of the Uterus
Status: Enrolling
Updated: 3/20/2018
State University of New York - Downstate Medical Center
mi
from
Brooklyn, NY
Click here to add this to my saved trials
Ixabepilone in Treating Patients With Recurrent or Persistent Uterine Cancer
A Phase II Evaluation of Ixabepilone (NSC #710428) in the Treatment of Recurrent or Persistent Carcinosarcoma of the Uterus
Status: Enrolling
Updated:  3/20/2018
Stony Brook University Medical Center
mi
from
Stony Brook, NY
Ixabepilone in Treating Patients With Recurrent or Persistent Uterine Cancer
A Phase II Evaluation of Ixabepilone (NSC #710428) in the Treatment of Recurrent or Persistent Carcinosarcoma of the Uterus
Status: Enrolling
Updated: 3/20/2018
Stony Brook University Medical Center
mi
from
Stony Brook, NY
Click here to add this to my saved trials
Ixabepilone in Treating Patients With Recurrent or Persistent Uterine Cancer
A Phase II Evaluation of Ixabepilone (NSC #710428) in the Treatment of Recurrent or Persistent Carcinosarcoma of the Uterus
Status: Enrolling
Updated:  3/20/2018
Duke Univ Med Ctr
mi
from
Durham, NC
Ixabepilone in Treating Patients With Recurrent or Persistent Uterine Cancer
A Phase II Evaluation of Ixabepilone (NSC #710428) in the Treatment of Recurrent or Persistent Carcinosarcoma of the Uterus
Status: Enrolling
Updated: 3/20/2018
Duke Univ Med Ctr
mi
from
Durham, NC
Click here to add this to my saved trials
Ixabepilone in Treating Patients With Recurrent or Persistent Uterine Cancer
A Phase II Evaluation of Ixabepilone (NSC #710428) in the Treatment of Recurrent or Persistent Carcinosarcoma of the Uterus
Status: Enrolling
Updated:  3/20/2018
Case Western Reserve Univ
mi
from
Cleveland, OH
Ixabepilone in Treating Patients With Recurrent or Persistent Uterine Cancer
A Phase II Evaluation of Ixabepilone (NSC #710428) in the Treatment of Recurrent or Persistent Carcinosarcoma of the Uterus
Status: Enrolling
Updated: 3/20/2018
Case Western Reserve Univ
mi
from
Cleveland, OH
Click here to add this to my saved trials
Ixabepilone in Treating Patients With Recurrent or Persistent Uterine Cancer
A Phase II Evaluation of Ixabepilone (NSC #710428) in the Treatment of Recurrent or Persistent Carcinosarcoma of the Uterus
Status: Enrolling
Updated:  3/20/2018
Cleveland Clinic Foundation
mi
from
Cleveland, OH
Ixabepilone in Treating Patients With Recurrent or Persistent Uterine Cancer
A Phase II Evaluation of Ixabepilone (NSC #710428) in the Treatment of Recurrent or Persistent Carcinosarcoma of the Uterus
Status: Enrolling
Updated: 3/20/2018
Cleveland Clinic Foundation
mi
from
Cleveland, OH
Click here to add this to my saved trials